Protectable inventions can arise at any stage of research and pharmaceutical clinical trials are no exception. At the stage of clinical trials, the active pharmaceutical ingredient (API) is typically already protected in a patent application, along with several follow-up secondary applications (including formulations and combinations).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Joseph Lenthall
The UPC Court of Appeal’s first decision: What does it mean for the assessment of inventive step at the UPC?
What does the decision mean for the assessment of inventive step at the UPC? Joseph Lenthall explores the first decision from the UPC’s Court of Appeal overturning a preliminary injunction, citing lack of inventive step in a patent dispute between 10X Genomics and Nanostring Technologies, and the implications for future patent validity assessments in Europe.
CASGEVY™ - World's First Approval Of A CRISPR/Cas9 Gene-Editing Therapy - Healthcare - UK
The UK Medicines and Healthcare products Regulatory Agency (MHRA) approved CASGEVY" for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) on 16 November 2023. This is the world's first approval of a therapy using CRISPR/Cas9 gene-editing technology. We explore this historic development in this article. The CRISPR/Cas9 system was discovered a little over ten years ago.
Webinar: Trade Secrets – Strategic Considerations To Maximise Value For The Business - - Worldwide
This one hour webinar will provide a comprehensive and practical guide to Trade Secrets, including pointers on when and how to incorporate Trade Secrets into a wider IP strategy, examples and discussion of key technology sectors, and best practice for identifying, documenting, and protecting Trade Secrets to maximise their value for the business. The presenters will cover: 1. What is a Trade secret and when is it useful?
Webinar: Trade Secrets – Strategic Considerations to Maximise Value for the Business
Please login to Mondaq or sign up for our free news alerts to be able to register for this webinar.
Of Course My Invention Works! Post-Published Evidence, Inventive Step And EPO Enlarged Board Of Appeal Referral G2/21
UK: Of Course My Invention Works! Post-Published Evidence, Inventive Step And EPO Enlarged Board Of Appeal Referral G2/21 19 November 2021 Haseltine Lake Kempner LLP Your LinkedIn Connections with the authors To print this article, all you need is to be registered or login on Mondaq.com. Post-published evidence can be used to assess inventive step at the EPO.
EPO Boards Of Appeal Launch Consultation To Give Board The Power To Hold Hearings By Videoconference
Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice): Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below. Mondaq has a "free to view" business model.
Claim One - #03 Strategic Portfolio Reviews (Video) - Strategy - UK
Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice): Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below. Mondaq has a "free to view" business model.
Claim One - #02 PPH (Video) - Intellectual Property - UK
Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice): Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below. Mondaq has a "free to view" business model.
Claim One - #01 EPO Oral Proceedings (Video) - Intellectual Property - UK
Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice): Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below. Mondaq has a "free to view" business model.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Joseph
Contact Joseph, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack